Evaluation of spray dried animal plasma and calcium formate as alternatives to colistin in piglets experimentally infected with Escherichia coli K99

Two trials were conducted to evaluate spray dried animal plasma and calcium formate as alternatives to preventive medication with colistin in piglets experimentally challenged with Escherichia coli K99. Two groups of newly weaned pigs were offered four treatments consisting of: Negative Control (NC); spray dried animal plasma (SDAP); calcium formate (CF) and colistin (COL). All animals were experimentally challenged with a single oral dose of E. coli K99. Their performance was recorded and, in the second trial, 6 piglets from each treatment were killed to obtain samples of jejunal mucosa for histological measurements and digesta from the ileum and the caecum for microbiological determinations. SDAP improved weight gain (P < 0.05) and feed intake (P < 0.06) in the first two weeks after weaning of trial 1, and a similar response, although not statistically significant, was found in trial 2. Colistin also resulted in a numerical improvement in performance, but calcium formate did not. No clear effects on mucosal histology were observed and only colistin had a significant effect on the microbiological composition of digesta.     

氟苯尼考与黏菌素联用对猪大肠杆菌与链球菌的体外抗菌作用

采用棋盘法,测定了氟苯尼考与黏菌素联用对猪大肠杆菌、链球菌分离株的体外抗菌活性。结果表明:猪大肠杆菌、链球菌分离株均对氟苯尼考呈现出耐药性,其最小抑菌浓度(MIC)为0.64~5.12 mg/L,大部分大肠杆菌分离株对黏菌素耐药,仅对其中一株有明显效果。棋盘法测得氟苯尼考与黏菌素联合对猪大肠杆菌、猪链球菌分离株的部分抑菌浓度(FIC)指数为0.031 26~0.140 63,均为协同作用。当浓度大于或等于0.16 mg/L时即呈现出协同作用。     

Determination of a dosage regimen of colistin by pharmacokinetic/pharmacodynamic integration and modeling for treatment of G.I.T. disease in pigs

Colistin is an antimicrobial drug of the polymyxin group and COLIVET SOLUTION is an aqueous solution containing colistin sulphate (2 × 10⁶ IU/mL), formulated for oral administration. The target species is the pig, particularly the suckling and post weaning animal. This investigation was undertaken to provide pharmacokinetic and pharmacodynamic data on which to base the selection of dosage rate and interval of the solution for the treatment of porcine colibacillosis.Colistin absorption from the gastrointestinal tract of young pigs, when administered at dosage rates of 25,000, 50,000 and 1,00,000 IU/kg, was slight or absent. The drug was therefore restricted almost entirely to the required site of action. The colistin concentration-time profile within the jejunum and ileum was established, and this enabled determination of the pharmacokinetic variables, maximum concentration (C_max) and area under curve (AUC) and derivation of the surrogate indices of antibacterial activity, C_max/minimum inhibitory concentration (MIC) and AUC/MIC through integration of in vivo data with the results of in vitro potency studies for four strains of Escherichia coli.In the in vitro bacterial growth inhibition studies colistin acted by a concentration-dependent killing mechanism. Numerical values for the surrogate parameter AUC/MIC producing bactericidal and eradication effects of colistin against four strains of E. coli were established by PK-PD modeling based on the sigmoidal E_max equation. These data were used to predict a daily dosage regimen for colistin.